Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) had its price target lowered by research analysts at HC Wainwright from $20.00 to $15.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Several other brokerages have also recently weighed in on ACTU. Weiss Ratings reissued a “sell (e+)” […]

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) had its price target lowered by equities researchers at HC Wainwright from $32.00 to $13.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 199.19% from the stock’s previous […]

Aprea Therapeutics (NASDAQ:APRE – Free Report) had its target price reduced by HC Wainwright from $4.00 to $1.20 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock. APRE has been the subject of a number of other reports. Wedbush decreased their price target on Aprea Therapeutics from $11.00 […]

HC Wainwright downgraded shares of Iterum Therapeutics (NASDAQ:ITRM – Free Report) from a buy rating to a hold rating in a research note published on Monday, MarketBeat reports. Several other equities research analysts have also weighed in on ITRM. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a report on […]